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ABSTRAK
Latar Belakang: Faktor genetik urolitiasis memainkan peran penting dalam etiologi. Penjelasan
gen yang bertanggung jawab dapat mengarah pada terapi dan pencegahan gen yang ditargetkan
dengan lebih baik di masa depan. Artikel ini bertujuan untuk menjelaskan berbagai faktor genetik
yang berperan dalam pembentukan batu ginjal. Metode: Sebuah tinjauan atikel tentang urolitiasis
berdasarkan pendekatan genetika dilaporkan mendasari pembentukan batu. Sejumlah 41 abstrak
dan artikel penelitian yang diterbitkan oleh jurnal yang bereputasi internasional dipilih
berdasarkan kata kunci faktor genetik dan urolithiasis Simpulan: Pemahaman yang lebih dalam
tentang faktor genetik yang berperan dalam mekanisme pembentukan batu serta kemajuan
molekuler dan farmakogenomik telah merevolusi diagnosis dan pengobatan, dan membuka jalan
untuk identifikasi target terapi baru dan pendekatan pengobatan berdasar rekayasa genetik.
Kata kunci : genetik, idiopatik, batu ginjal
ABSTRACT
Background: The genetic factor of urolithiasis plays an important role in the etiology.
Elucidation of responsible genes can lead to better targeted gene therapy and prevention in the
future. This article aims to explain various genetic factors that play a role in kidney stone
formation Method: A review article on urolithiasis based on a genetic approach is reported to
underlie stone formation. A total of 41 abstracts and research articles published by
internationally reputed journals were selected based on the keywords genetic factors and
urolithiasis. Summary: A deeper understanding of the genetic factors that play a role in the
mechanisms of stone formation and advances in molecular and pharmacogenomics have
revolutionized diagnosis and treatment, and paved the way for the identification of new
therapeutic targets and treatment approaches based on genetic engineering.
Keywords: Genestic, idiopathic, urolithiasis, kidney stone
INTRODUCTION
The Urolithiasis is derived from the words
Urolithiasis = ouron (urine, urine) and lithos
(stone, stone, crystal), which is the formation of
stones in the urinary system, Nephroliths (called
renal calculi, ren, renes (Latin), kidney and
calculi, pebbles in the language aesculapian,
also called nephrolithiasis or urolithiasis,
accumulation of minerals or other material
forms forming minor stones in the kidneys,
ureters or bladder (Smith et al,, 2010).
The prevalence of urolithiasis worldwide
ranges from 7% to 13% in North America, 5-9%
in Europe, and 1 - 5% in Asia (Sorokin et al,
2017). Because of the high recurrence rate of
urolithiasis, the American Urological
Association (Pearle et al, 2015) and the
European Association of Urology (Türk et al,
2016) recommend to manage and prevent future
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recurrence by assessing dietary and medical
treatment.
The increased prevalence of kidney stones
is a global phenomenon. Data from five
European countries, Japan, and the United
States show that the incidence and prevalence of
stone disease have increased over time
throughout the world (Romero et al, 2010).
Genetic factors have been postulated to play an
important role in the risk of urolithiasis, such as
a positive family history is a well-known risk
factor for urolithiasis. The rate of disease
association in monozygotic twins is higher than
dizygotic twins (32.4% vs 17.3%) (Goldfarb et
al, 2005).
Single gene mutation states such as
cystinuria are known to cause nephrolithiasis in
a small proportion of stone patients (Monico et
al, 2011). Genetic factors that contribute to
patients with idiopathic stone formation are little
known, various studies have been attempted to
explain the pathology of lithogenesis, but the
exact mechanism associated with stone
formation is still not fully understood. Several
risk factors have been identified as causes of
kidney stone formation, such as dietary,
infections, low fluid intake, metabolic disorders
and genetic factors. In this review, we identify
genetic factors that play a role in the formation
of kidney stones based on the results of the
research conducted from 1999 to 2016.
METHOD
A review article on urolithiasis based on a
genetic approach is reported to underlie stone
formation. A total of 41 abstracts and research
articles published by internationally reputed
journals were selected based on the keywords
genetic factors and urolithiasis.
The following genes are reported to have a
possible causative role in urolithiasis: (1) Stone
molecule matrix (Osteopontin, OPN), (2) Genes
related to calcium regulation (eg: calcium
sensing receptor (CASR); claudin 14 (CLDN14);
calcium active-release calcium modulator 1
(ORAI1); (3) Genes related to calcium
regulation/phosphate (eg: vitamin D (VDR);
klotho (KL); sodium hydrogen antiporter 3
regulator 1 (NHERF1); fibroblast growth factor
23 (FGF23); and calcitonin receptor (CALCR),
(4) Genes Related to Urinary Inhibitors of Stone
Formation (e.g. Solute carrier family 13 member
2; Prothrombin); (5) Genes Related to anti-
inflammatory and antioxidative stress (e.g.
Interleukin 1 receptor antagonist, Paraoxonase-1,
Genes for uric acid stones), (6) Other Genes (eg.
Phosphate carrier NPT2a, Aquaporin-1, Diacyl
glycerol kinase, Alkaline phosphatase, and
Transient receptor potential cation channel
subfamily V member 5) and (7) Monogenic
urolithiasis
RESULT AND DISCUSSION
1. Stone Macromolecule Matrix.
Several macromolecules, such as
Tamm-Horsfall glycoprotein, osteopontin,
bikunin, and nephrocalcin have been detected
in patients with calcium oxalate kidney
stones. The role of single nucleotide
polymorphisms in genes that encode these
substances and the risk of idiopathic calcium
oxalate stone formation has been examined.
A strong association of several SNPs in
Osteopontin genes (T-593A, C6982T,
rs1126616, -156delG) with urinary stone
formation in populations of Turkey, Japan
and Taiwan has been demonstrated. (Xiao et
al, 2016). Likewise, polymorphism (I550V)
in the gene coding for cotransporter Na + /
dicarboxylate (hNaDC-1), the main regulator
of urinary citrate excretion has been shown to
be associated with the risk of repeated
calcium-containing stones. (Okamoto et al,
2007). Urinary citrate is a powerful inhibitor
of calcium oxalate crystal formation in
human urine. Homozygous patients for this
variant show significantly lower urinary
citrate.
Indonesian Journal of Pharmacy and Natural Product
http:/jurnal.unw.ac.id/index.php/ijpnp
Volume 04, Nomor 02 , Sepetember 2021
p-ISSN : 2656-3215
e-ISSN : 2615-6903
Submitted: 5 Mei 2021 Revised : 20 July 2021 Accepted : 30 August 2021 125
Osteopontin (OPN) is a highly
phosphorylated glycoprotein that was
initially identified in bone that functions as a
protein adhesion motif to integrins and CD44,
also identified as one of the organic
components (matrix) of calcium-based
urinary stones. The OPN Knock Out rat
research report produces Calcium oxalate
(CaOx) crystals (Tzou et al, 2016), whereas
other studies show that the OPN facilitates
the development of crystals by the process of
mineralization and inflammation mediated by
other cytokines and immune cells including
macrophages (Joshi et al, 2017).
There is a controversial function, OPN
is a constituent of the stone matrix, also
known as a specific monocyte
chemoattractant in the kidney interstitium,
plays a role in suppressing nucleation and
aggregation of CaOx crystals in vitro;
conversely OPN knockdown in
hyperoxaluric mice can cause a reduction in
CaOx crystal deposition (Tsuji et al, 2014),
several reports of OPN produce CaOx
crystals (Tzou et al, 2016)
Extracellular OPN functions through
interactions with cell surface receptors,
including integrins (avb1, avb3, avb5, avb6,
a4b1, a5b1, a5b1, a8b1, and a9b1) and CD44
which regulate cellular processes such as bio-
mineralization, tissue remodeling and
immune regulation
OPN can directly bind the surface of
certain apatite crystals so that it regulates its
function as an inhibitor of mineralization.
OPN is not only important for bone
mineralization, but is also regulated in
ectopic sites, pathological phytochemicals
such as vascular calculus, valvular
circulation, renal crystal formation, and
gallstone formation (Kahles et al, 2014).
2. Calcium Regulation Genes
2.1. Calcium-sensing receptor (CASR)
CASR is a protein G paired receptor that
modulates cell activity, according to
extracellular calcium concentration. This
protein is expressed in the parathyroid gland
and the thick ascending limb loop of Henle.
Its activation encourages increased calcium
excretion in the kidneys through regulation
of parathyroid hormone production (PTH)
and renal tubular calcium reabsorption
(Vezzoli et al, 2013).
Studies from Italy have suggested a
relationship between a single functional
nucleotide polymorphism (R990G) which is
rare from the CaSR gene (chromosome
3q13.3–21.1), which causes an increase in
receptor function, and hypercalciuria in 124
women recruited from outpatient
osteoporosis. (Vezzoli et al, 2007), But the
nonparametric relationship and quantitative
nature analysis in 64 Canadian siblings of
calcium oxalate and kidney stone phosphate
with varying degrees of calciuria did not
reveal an association with microsatellite
markers in the CaSR gene region.
2.2. Claudin 14 (CLDN14)
CLDN14 is a member of the claudin
protein membrane family that regulates
parts of paracellular ions and small solutes
in tight junctions of the epithelium.
CLDN14 is expressed in the kidneys, both
in the Henle loop and in the proximal
tubules, as well as in the epithelium of
several other organs, and has been
selectively observed to reduce the
permeability of Ca2+ (41_TD $ DIF) through
tight junctions.(Thorleifsson et al, 2009)
Studies have shown that CLDN14
expression is highly regulated by CASR
activation, and disregulation of the kidney
CASR. CLDN14 pathway can contribute to
the development of kidney stones (Guha et
al, 2015).
2.3. Calcium release-activated calcium
modulator-1.
ORAI-1 is a membrane calcium
channel subunit that is activated when
calcium deposits run out. These gene
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mutations produce deficiencies in signaling
pathways that depend on the calcium
reserves that are operated, which leads to
immune system dysfunction. (Chou et al,
2011).
3. Calcium/Phosphate Regulation genes
3.1. Vitamin D receptor.
This gene codes for the nuclear
hormone receptor for vitamin D3. It plays
a central role in mineral metabolism,
including intestinal calcium absorption and
renal calcium absorption.( Lin et al, 2011).
3.2. Klotho.
Klotho is a type-I transmembrane
protein associated with β-glucosidase, a
new regulator of calcium and phosphate
homeostasis. Klotho is expressed in tissues
responsible for calcium homeostasis,
including the kidneys, parathyroid glands,
and choroidal plexus epithelium in the
brain. Klotho also plays an important role
in increased calcium uptake in the kidneys
via TRPV5 phosphate homeostasis via
FGF23. (Telci et al, 2011; Xu et al, 2013).
3.3. Sodium hydrogen antiporter 3 regulator-
1.
NHERF1, also known as SLC9A3R1,
binds renal tubular transporters including
the Na+ (37_TD$DIF) phosphate co-
transporter 2a (NPT2a) and the PTH type
1 receptor. NHERF1 knockout mice
demonstrate increased urinary calcium,
phosphate, and uric acid excretion, with
resultant renal calcium phosphate crystal
deposits (Tzou et al, 2016).
3.4. Fibroblast growth factor 23.
The recently identified growth factor
(FGF-23) regulates renal phosphate
homeostasis by reducing renal
reabsorption and intestinal absorption.
FGF23 reduces phosphate by
downregulating NPT2 co-transporters,
resulting in urinary phosphate wasting. It
also acts to decrease serum phosphorus
levels by reducing the bioavailability of
vitamin D3 (Telci et al, 2011; Rendina et
al, 2013).
3.5. Calcitonin receptor.
Calcitonin, a 32 amino acid protein,
binds to the CALCR receptor in bone
osteoclasts as well as in kidney tubular
cells. Calcitonin acts as a renal calcium-
conserving hormone by increasing Ca2+
and Mg2+ reabsorption and decreasing
phosphate reabsorption in the kidneys.
CALCR polymorphisms are reported to
be associated with changes in bone
mineral density in different populations,
several studies have established an
association of SNP with urolithiasis
(Atmoko et al, 2021).
4. Urinary Inhibitors of Stone Formation
genes
4.1. Solute carrier family 13 member 2.
SLC13A2 is located on chromosome
17q11.2, consists of 14 exons, and encodes
Na + / dicarboxylate cotransporter-1
(NaDC-1). NaDC-1 plays an important
role in citrate reabsorption in the apical
membrane of the proximal tubule; this
protein is the main determinant of urinary
citrate excretion. Genetic predisposition
rather than metabolic abnormality may
thus be a major cause for idiopathic
hypocitraturia generating interest in
NaDC-1 (Okamoto et al, 2007).
4.2. Prothrombin.
Prothrombin is also known as
coagulation factor II, a serin-protease
coagulation protein in the bloodstream that
converts soluble fibrinogen into insoluble
fibrin strands and catalyzes many other
coagulation-related reactions. Prothrombin
synthesis is controlled by F2. Urinary
prothrombin fragment 1 (UPTF1), was
initially detected as a crystal matrix
protein within calcium oxalate crystals,
and it is considered to be a potent inhibitor
of calcium oxalate growth and aggregation
in urine (Rungroj et al, 2012).
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5. Antiinflammatory and antioxidative
stress genes
5.1. Interleukin 1 receptor antagonist.
Interleukin (IL) -1 is one of the main
proinflammatory cytokines that facilitate
tissue inflammation. Its receptor, IL-1
receptor antagonist, is encoded by IL-RN
and exhibits anti-inflammatory function by
binding to the same receptor as IL-1a and
IL-1b. (Çoker Gurkan et al, 2013).
5.2. Paraoxonase-1 (PON 1)
PON1 is a serum enzyme bound to
high density lipoprotein that functions as
an antioxidant. Its activity is reduced in an
environment of high oxidative stress and is
associated with increased lipid
peroxidation, which is a factor in
determining the tendency for stone
formation. (Atar et al, 2016).
5.3. Genes for uric acid stones.
A study reports the possible
relationship of SNP in caspase activation
and domain 8 gene (CARD8) in the
formation of stones with gout (uric acid)
(Chen et al, 2015). CARD8 is an innate
immune component involved in suppressing
NF-kB activation. CARD8 suppresses the
immune response and inflammatory activity.
CARD8, also known as NDPP; DACAR;
DAKAR; NDPP1; TUCAN; CARDINAL is
an innate immune component involved in
the suppression of activation of the core
factor KB. CARD8 suppresses the immune
response and inflammatory activity, which
is located on chromosome 19q13.33 and
consists of 22 exons. (Chen et al, 2015)
6. Genes in hyperoxaluria
6.1. Pimary hyperoxaluria-1 (OMIM259900)
Persistent and marked hyperoxaluria
is proven from infancy, although the level
of hyperglycolic aciduria varies. More than
100 mutations in the gene coding for AGT
(AGXT, 2q37.2) have been described.
Molecular diagnosis is possible in most
patients (Williams et al, 2009). About a
third of patients experience a significant
reduction in urinary oxalate excretion when
receiving a pharmacological dose of
vitamin B6, a response that has been
associated with the most common
mutations (c.508 G> A, G170R), which
causes a unique peroxisome - a defect in
mitochondrial trade. (Monico et al, 2005).
6.2. Pimary hyperoxaluria-2 (OMIM260000)
Lack of cytosolic activity of liver
glyxylate / hydroxyprovatase reductase
(GRHPR) causes PH2 (Giafi, & Rumsby,
1998). GRHPR has multiple enzymatic
activity, catalyzes the reduction of
glycylates to glycolic and hydroxypyronate
to D-glycerate in the human heart.
6.3. Pimary hyperoxaluria-3
Primary hyperoxaluria (PH3) has been
clinically recognized for some time in
patients with early onset nephrolithiasis and
is characterized by hyperoxaluria that
cannot be distinguished from PH1 and PH2
but the liver's AGT and GRHPR activity is
normal. (Monico et al, 2002)
Mutations in the HOGA1 gene have
been determined to be
responsible.(Belostotsky et al, 2010) This
disease appears to be autosomal recessive,
although its inheritance is not yet fully
understood. (Monico et al, 2011).
Hyperoxaluria is believed to be the result of
a deficiency of the 4-hydroxy-2-
oxoglutarate aldolase liver mitochondrial
enzyme. Early experience shows that the
prevalence of PH3 is similar to PH2.
(Monico et al, 2011).
7. Other Genes
7.1. Phosphate carrier NPT2a.
SLC34A1, a member of the type IIa
sodium phosphate cotransporter family.
NPT2a is responsible for phosphate
absorption at the apical membrane of renal
proximal tubular cells. (Yasui et al, 2013)
NPT2a knockout mice demonstrate
hypercalciuria and renal calcium phosphate
Indonesian Journal of Pharmacy and Natural Product
http:/jurnal.unw.ac.id/index.php/ijpnp
Volume 04, Nomor 02 , Sepetember 2021
p-ISSN : 2656-3215
e-ISSN : 2615-6903
Submitted: 5 Mei 2021 Revised : 20 July 2021 Accepted : 30 August 2021 128
crystal deposits (Tzou et al, 2016).
Mutations of SLC34A1 appear to be
associated with hypophosphatemic
nephrolithiasis and osteoporosis in
humans.( Yasui et al, 2013).
7.2. Aquaporin-1
Aquaporin-1 is a family of small
integral membrane proteins associated with
the main intrinsic protein (MIP or AQP0).
This gene encodes an aquaporin which
functions as both a molecular water channel
protein and as a non-selective cation
channel gated by cyclic guanosine
monophosphate (cGMP).(Boassa, & Yool,
2003) Aquaporin-1 is widely expressed in
the kidneys, especially in the proximal
tubule, and has a function as a water
channel. Aqp1 knockout mice exhibit
reduced osmotic permeability and
developed hydration after lack of water
7.3. Diacyl glycerol kinase, (DGKH)
DGKH is is a family of enzimes taht
catalyzes the conversion of Diacylglycerol
(DAG) to phosphatidic acid, utilizing ATP
as a source of the phosphate. expressed in
the brain and has been known to be
associated with psychiatric disorders such
as bipolar disorder and major depression.
DGKH is a DGK family, which is involved
in the entry of transplasmalemmal calcium
ions. (Xu et al, 2014).
7.4. Alkaline phosphatase.
Alkaline phosphatase (ALP), one kind
enzyime found in the body, a member of
the alkaline phosphatase family as a tissue
nonspecific form and a membrane-bound
glycosylated enzyme. ALP is expressed in
the proximal tubules of the kidney and
hydrolyzes pyrophosphate to free phosphate,
suggesting its facilitating role in kidney
stone formation
7.5. Transient receptor potential cation channel
subfamily V member 5.
TRPV5 is a highly selective epithelial
calcium channel expressed at the apical
membrane of the distal renal tubule
epithelial cells, which mediates calcium
transport in the kidney and constitutes the
rate-limiting step of active calcium
reabsorption.
TRPV5 (- / -) mice showed significant
impairment in calcium homeostasis similar
to human patients with idiopathic
hypercalciuria,( Hoenderop et al, 1999)
including marked hypercalciuria, increased
absorption of dietary calcium, increased
levels of vitamin D, and disorders of the
bone (reduced trabecular and cortical mass),
suggesting a major regulatory role for
TRPV5. The encoding of the human gene
for TRPV5 is located on chromosome
7q35.43. Screening of the TRPV5 molecule
in 20 patients with renal hypercalciuria
revealed 8 changes in a single nucleotide
base, but functional characterization of this
variant failed to show differences from wild
type TRPV5.( Renkema et al, 2009).
7.6. Cystinuria (OMIM 220100)
Cystinuria is an autosomal recessive
trait, caused by renal reabsorption and
proximal gastrointestinal damage from
cystine and dibasic amino acids due to
mutations in genes (SLC3A1 and SLC7A9)
that encode these amino acid carriers.
(Feliubadaló et al, 1999)
7.7. Xanthinuria / Hypoxanthinuria (lack of
XDH) (OMIM 278300)
Lack of xanthine dehydrogenase (XDH)
due to mutations in the XDH gene (2p22)
also results in impaired purine degradation,
in this case characterized by an increase in
xanthine and hypoxanthine in the urine but
with hypouricemia and hypouricosuria.
This disease is more common in the
Mediterranean and Middle East regions of
the world and is inherited as an autosomal
recessive trait. (Torres, & Puig, 2007).
7.8. Lack of HPRT (HPRT, EC 2.4.2.8)
(MIM300322)
The important physiological role of
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hypoxanthine-guanine phosphorybosil-
transferase (HPRT) activity in the human
purine metabolism (emphasized by its
absence, which results in Lesch-Nyhan
syndrome (MIM300322), is characterized
by hyperuricemia, hyperikicosuria,
urolithiasis of early uric acid (most
common) in the year of the first life) and
neurological complications (mental
retardation and self-mutilation).
In the case of partial HPRT enzyme
deficiency, which is referred to as Kelley-
Seegmiller syndrome, less severe
phenotypic manifestations are observed (e.g.
hyperuricemia, gout), partially correlated
with the rest of the HPRT enzymatic
activity. Both syndromes result from
personal or de novo mutations in the X-
linked HPRT1 gene (Xq26-q27.2), with>
300 mutations described so far (Torres et al,
2007).
7.9. Genes for atazanavir-containing stones
(OMIM UGT1A1)
Nephrolithiasis induced by atazanavir
is a rare condition among all uroliths, and
the exact mechanism for stone formation is
not fully understood. UDP glucuronosyl
transferase family 1 member A1 (UGT1A1)
is expressed mainly in the liver and
digestive tract, and plays a role in the
elimination of bilirubin. Given that
UGT1A1 is known for its association with
atazanavir unconjugated hyper-
bilirubinemia, this is also thought to be
involved in atazanavir metabolism.
8. Monogenic urolithiasis




transferase deficiency (HPRT) and family
hypomagnesemia deficiency with
hypercalciuria and nephrocalcinosis
(FHHNC) in particular, are associated with
kidney failure. The formation of crystals in
the kidney tubules in this condition results
in an adverse inflammatory response that
causes interstitial fibrosis and the
development of end-stage renal disease
(ESRD). Major genetic defects, classified
based on metabolic risk factors for stone
formation (Relan et al, 2004)
CONCLUTION
Urolithiasis is a common urology problem.
In most cases, this multifactorial pathology
develops due to a combination of inherited low-
gene variants and environmental factors. The
influence of genes on polygenic and monogenic
urolithiasis has developed rapidly, giving rise to
an appreciation for the participatory role of
various proteins, including enzymes,
transporters, channels and receptor proteins in
the kidneys and other system organs.
A deeper understanding of the genetic
factors that play a role in the mechanisms of
stone formation and advances in molecular and
pharmacogenomics have revolutionized
diagnosis and treatment, and paved the way for
the identification of new therapeutic targets and
treatment approaches based on genetic
engineering.
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